semaglutide and optic neuritis Non-arteritic Anterior Ischemic Neuropathy: A Systematic Review Investigating the Link Between Glucagon-Like

Self-administration or the use of unauthorized products carries significant risks and can lead to undesirable outcomes

E.CaoX.StreutkerC

Observational and preclinical data suggest that GLP-1 receptor activation may reduce neuroinflammation and slow the accumulation of amyloid and tau pathology associated with Alzheimer's disease, and semaglutide is currently in Phase 3 trials for both Alzheimer's disease and Parkinson's disease [12]

Animal models of Achilles tendon injury show BPC-157 treatment significantly improves recovery as evidenced by biochemical markers and microscopic observations

doi: 10.3389/fnut.2025.1549782 29 ValenteMGarboRFilippiFAntonuttiACeccariniVTereshkoYet al

A meta-analysis of adults with knee OA and obesity found that a 5% to 10% weight loss significantly improved pain, self-reported disability, and physical quality of life ( 5.4 Positioning GLP-1 receptor agonists among obesity-treatment options GLP-1 receptor agonists should be positioned within the broader continuum of obesity treatment rather than presented as a replacement for existing strategies